Clicky

CRISPR Therapeutics AG(CRSP)

Description: Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.


Keywords: Biology Immune System Acid Enzymes Genetics Genetic Engineering Serious Diseases Precision Medicine DNA CRISPR Genome Editing Cas9

Home Page: www.crisprtx.com

CRSP Technical Analysis

Baarerstrasse 14
Zug, 6300
Switzerland
Phone: 41 41 561 32 77


Officers

Name Title
Dr. Samarth Kulkarni Ph.D. CEO & Director
Mr. Brendan Smith M.B.A. Sr. VP, CFO & Principal Accounting Officer
Dr. Lawrence Otto Klein Ph.D. Chief Operating Officer
Mr. James R. Kasinger Gen. Counsel & Sec.
Dr. Rodger Novak M.D. Founder, Chairman & Pres
Mr. Shaun Foy Founder
Dr. Emmanuelle Marie Charpentier Co-Founder & Scientific Advisory Board Member
Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member
Dr. Chad A. Cowan Ph.D. Scientific Founder
Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 23.3645
Trailing PE: 12.4149
Price-to-Book MRQ: 2.0111
Price-to-Sales TTM: 253.2571
IPO Date: 2016-10-19
Fiscal Year End: December
Full Time Employees: 473
Back to stocks